Nuclear receptor therapies for liver and metabolic disease
Metacrine is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver, gastrointestinal, and metabolic diseases. The company targets nuclear receptors involved in disease pathways, with a pipeline aimed at conditions such as NASH and inflammatory bowel disease.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountSep 2020
Jun 2018
Dec 2017
Aug 2015
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
